Pharmaceutical

Hanmi and MEDiC ink cancer biomarker collaboration deal

The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.

Oct 16, 2024 - 04:00
Hanmi and MEDiC ink cancer biomarker collaboration deal
The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.
Read the original article

Tags:

Previous Article

Cell and gene therapy approvals drive paradigm change in manufacturing

Next Article

Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC grants marketing authorisation for Sandoz’s biosimilar Hyrimoz

EC grants marketing authorisation for Sandoz’s biosimil...

Apr 3, 2023

STAT+: Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says

STAT+: Merck CEO refused to testify in Senate because h...

Jan 28, 2024

Eloxx repackages ELX-02 data in cystic fibrosis as it eyes pivotal trial

Eloxx repackages ELX-02 data in cystic fibrosis as it e...

Jun 15, 2023